Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder that exerts a huge burden on our society. The occurrence of this neurodegenerative disease has been increasing day-by-day. PD can be a serious concern if the patients are left untreated. However, conventional treatment has many side-effects and less bioavailability in the brain. Therefore, the necessary measurement is required to solve the limitations of PD treatment. Nanotechnology has made a major contribution to comprehend PD pathogenesis. Nanotechnology can provide efficient therapies that have reduced side-effects and increased bioavailability in the brain. This review emphasizes the emerging promise of nanoparticle-based treatment, drug delivery, and other therapeutic approaches for PD. Besides, the advantages of different approaches on nanotechnology platforms are far better over conventional therapy in the treatment of PD.
Keywords: Parkinson's disease, progressive neurodegenerative disorder, nanotechnology, nanoparticles, α-synuclein, blood-brain barrier.
Graphical Abstract
Current Drug Metabolism
Title:Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease
Volume: 22 Issue: 7
Author(s): Md. Marufur Rahman Moni, Mst. Marium Begum, Md. Sahab Uddin*Ghulam Md Ashraf*
Affiliation:
- Department of Pharmacy, Southeast University, Dhaka,Bangladesh
- Pre-clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah,Saudi Arabia
Keywords: Parkinson's disease, progressive neurodegenerative disorder, nanotechnology, nanoparticles, α-synuclein, blood-brain barrier.
Abstract: Parkinson’s disease (PD) is a progressive neurodegenerative disorder that exerts a huge burden on our society. The occurrence of this neurodegenerative disease has been increasing day-by-day. PD can be a serious concern if the patients are left untreated. However, conventional treatment has many side-effects and less bioavailability in the brain. Therefore, the necessary measurement is required to solve the limitations of PD treatment. Nanotechnology has made a major contribution to comprehend PD pathogenesis. Nanotechnology can provide efficient therapies that have reduced side-effects and increased bioavailability in the brain. This review emphasizes the emerging promise of nanoparticle-based treatment, drug delivery, and other therapeutic approaches for PD. Besides, the advantages of different approaches on nanotechnology platforms are far better over conventional therapy in the treatment of PD.
Export Options
About this article
Cite this article as:
Moni Marufur Rahman Md. , Begum Marium Mst. , Uddin Sahab Md. *, Ashraf Md Ghulam*, Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease, Current Drug Metabolism 2021; 22 (7) . https://dx.doi.org/10.2174/1389200222666210202110129
DOI https://dx.doi.org/10.2174/1389200222666210202110129 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Use of Stem Cells in Regenerative Medicine for Parkinson’s and Huntington’s Diseases
Current Medicinal Chemistry Pharmacogenetics and Drug Therapy in Psychiatry - The Role of the CYP2D6 Polymorphism
Current Pharmaceutical Design The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Mobile Phone Text Message Interventions in Psychiatry - What are the Possibilities?
Current Psychiatry Reviews Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Organometallic Complexes: New Tools for Chemotherapy
Current Medicinal Chemistry Deprescribing for Psychiatry: The Right Prescription?
Current Psychiatry Reviews Rhinosinusitis in the Pediatric Patient with Cystic Fibrosis
Current Pediatric Reviews Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Conference Report: 9th International Summer School of Neurology
CNS & Neurological Disorders - Drug Targets Partial Dopamine Agonists and Dopaminergic Stabilizers, in the Treatment of Psychosis
Current Drug Targets - CNS & Neurological Disorders Potential of Antibiotics for the Treatment and Management of Parkinson's Disease: An Overview
Current Drug Research Reviews Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson`s Disease
CNS & Neurological Disorders - Drug Targets Bipolar Affective Disorder in Young People: A Review
Adolescent Psychiatry Neuropeptidomics: Improvements in Mass Spectrometry Imaging Analysis and Recent Advancements
Current Protein & Peptide Science AMPA Receptor Potentiators: Application for Depression and Parkinsons Disease
Current Drug Targets Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART I
Current Neuropharmacology Pharmacological Studies of Smooth Pursuit and Antisaccade Eye Movements in Schizophrenia: Current Status and Directions for Future Research
Current Neuropharmacology Homocysteine and Hyperhomocysteinaemia
Current Medicinal Chemistry Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia
Current Neuropharmacology